Dysregulated fibroblast growth factor (FGF) signaling has been implicated in the pathogenesis of human cancers. Aberrant activation of FGF receptor 2 (FGFR2) signaling, through overexpression of FGFR2 and/or its ligands, mutations, and receptor amplification have been found in a variety of human tumors. We generated monoclonal antibodies (mAbs) against the extracellular ligand binding domain of FGFR2 to address the role of FGFR2 in tumorigenesis and to explore the potential of FGFR2 as a novel therapeutic target. We surveyed a broad panel of human cancer cell lines for the dysregulation of FGFR2 signaling and discovered that breast and gastric cancer cell lines harboring FGFR2 amplification predominantly express the IIIb isoform of the receptor. Therefore, we used an FGFR2-IIIb specific antibody, GP369, to investigate the importance of FGFR2 signaling in vitro and in vivo. GP369 specifically and potently suppressed ligand-induced phosphorylation of FGFR2-IIIb and downstream signaling, as well as FGFR2-driven proliferation in vitro. The administration of GP369 in mice significantly inhibited the growth of human cancer xenografts harboring activated FGFR2 signaling. Our findings support that dysregulated FGFR2 signaling is one of the critical oncogenic pathways involved in the initiation and/or maintenance of tumors. Cancer patients with aberrantly activated/amplified FGFR2 signaling could potentially benefit from therapeutic intervention with FGFR2-targeting antibodies.
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Copyright © 2010 American Association for Cancer Research 8 express high levels of FGFR2 protein as detected by Western analysis (data not shown) and flow cytometry ( Fig 1C) .
Identification and characterization of FGFR2 antagonistic antibodies.
In order to investigate the role of dysregulated FGFR2 signaling in tumor cell lines with FGFR2 amplification, FGFR2 specific monoclonal antibodies were generated. To establish cell-based assays to screen for functional FGFR2 antibodies, we first engineered IL-3 dependent murine Ba/F3 (pro-B) and FDCP-1 (bone marrow) cells to express wild type (WT) and cancer-associated mutant variants of FGFR2. Previous studies have demonstrated that ectopic expression of FGFRs in these cells confers FGF1-dependent proliferation in the absence of IL-3 (4, 5). As expected, there was no detectable proliferation of FDCP-1 cells stably expressing WT FGFR2 in the absence of IL-3 and FGF1 (data not shown). It is known that FGF1, 3, 7, 10 and 22 transduce signals through FGFR2-IIIb, whereas FGFR2-IIIc responds to a broader panel of ligands including FGF1, 2, 4, 6, 9, 16, 17, 18 and 20 (4, 5) . Similarly, the proliferation of FDCP-1 cells expressing the IIIb isoform of FGFR2 was stimulated by FGF7 and FGF10 but not by FGF2 and FGF9, whereas the proliferation of those expressing the IIIc isoform was enhanced by FGF2 and FGF9 specifically ( Supplementary Fig 1) .
Antibody secreting hybridomas were generated from mice immunized with the extracellular domain of human FGFR2. Primary screens using the engineered FDCP-1 cell lines identified a highly potent and selective isoform-specific FGFR2 mAb, GP369, that exhibited marked inhibition of proliferation driven by the IIIb, but not the IIIc isoform of FGFR2.
Octet analysis revealed specific binding of GP369 to human and mouse FGFR2-IIIb, but not to human FGFR2-IIIc or a negative control protein, human Jag1 (Fig 2A) . Surface plasmon resonance confirmed that GP369 exhibited similar affinity towards murine, cynomolgus, and on April 20, 2017. © 2010 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Copyright © 2010 American Association for Cancer Research 9 human FGFR2-IIIb Fc fusion proteins. No binding to human FGFR2-IIIc, or FGFR1-IIIb or FGFR3-IIIb was detected (data not shown). These results demonstrate that GP369 is an isoform specific antibody that binds to FGFR2-IIIb from mouse to human.
To understand the molecular interaction between GP369 and FGFR2-IIIb, we tested binding of GP369 to ten overlapping peptides covering the C-terminal half of the third Ig domain of human FGFR2-IIIb as this is the only region that differs between the IIIb and IIIc form.
Peptides 4, 5 and 6 showed strong binding to GP369 ( Fig 2B) , whereas the seven neighboring peptides did not exhibit any significant binding to GP369 ( Fig 2B) . Crystallographic structure of FGFR2-IIIb complexed with FGF10 has revealed critical residues within FGFR2-IIIb involved in direct binding with FGF10 (35). The GP369 binding epitope contains some of these residues important for ligand binding (Fig. 2C ). For example, Ser-315, Gly-316 and Ala-322 form hydrogen bonds with FGF10 whereas Ile-317 contacts FGF10 via hydrophobic interactions.
Therefore, binding of GP369 to FGFR-IIIb is likely to directly block ligand-receptor interaction.
GP369 inhibits WT and cancer-relevant mutant FGFR2-IIIb-driven proliferation.
We quantified the potency of GP369 by using FDCP-1 cells expressing either the IIIb or IIIc isoform of FGFR2. GP369 significantly inhibited, in a dose-dependent manner, the proliferation of FDCP-1 cells driven by FGFR2-IIIb (with an average IC 50 of approximately 1.4nM) but not by FGFR2-IIIc (Fig. 3A ). Breast and gastric cancer cell lines, such as SUM52PE and KATO III, express a C-terminally truncated variant of FGFR2 with increased transforming activity due to constitutive phosphorylation of FRS2 and activation of downstream signaling (36, 37) . GP369 also effectively suppressed the proliferation of FDCP-1 cells driven by this truncated FGFR2 variant ( Fig. 3A ). FGFR copy number of human cancer cell lines. qPCR was carried out using primers specific for
FGFRs or a reference gene, transketolase (TKT), and copy number was calculated. B. FGFR expression analysis. qRT-PCR was carried out using primers specific for FGFRs and HPRT.
The expression levels were normalized to HPRT. C. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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The amino acids involved in binding to FGF10 are highlighted in yellow. The peptides that bind to GP369 are denoted with "+" and those that don't bind are denoted with "-". Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Copyright © 2010 American Association for Cancer Research 24 ug/ml of either mIgG or GP369 for 1 hour at 37 o C prior to treatment with either heparin (20 ug/ml) or heparin plus FGF7 (30 ng/ml) for 15 minutes. Western blotting analysis was then carried out. C. Downregulation of the FGFR2 protein levels by GP369. SNU-16 cells were treated with 10 ug/ml of either mIgG or GP369. The cells were harvested at various time points.
Total levels of FGFR2 and β-Tubulin were determined by Western blotting and densitometric units quantified using Scion Image software. 
